Rachel A. McNamee

Rachel A. McNamee

Auto-generated profile, based on publicly available information

Rachel A. McNamee

‡Georgia Health Sciences University, Augusta, GA 30912

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Hypertension
Verified
Journal Article
Closed access
PDF file
Inna P. GladyshevaInna P. Gladysheva
Inna P. Gladysheva
DWDong Wang
Dong Wang
RMRachel A. McNamee
Rachel A. McNamee
AHAiilyan K. Houng
Aiilyan K. Houng
AMAlmois A. Mohamad
Almois A. Mohamad
GRGuy L. Reed
Guy L. Reed
Heart failure, caused by dilated cardiomyopathy and other cardiac disorders such as hypertension, is a major public health problem with high morbidity and mortality. Corin, a cardiac enzyme that cleaves natriuretic peptides, is a promising biomarker of cardiomyopathy and heart failure, but its functional role in these processes is not understood. We evaluated the potential effects of corin in mice with a well-characterized model of dilated cardiomyopathy. Mice with dilated cardiomyopathy developed heart failure, reduced contractile function, cardiac fibrosis, and accelerated mortality in the setting of low corin expression. In wild-type mice, transgenic, cardiac-targeted, overexpression of corin enhanced cyclic guanosine monophosphate and blood pressure responses to pro-atrial natriuretic peptide, but did not affect heart size, contractility, body weights, survival, and blood pressure. In mice with dilated cardiomyopathy, corin overexpression significantly reduced the development of myocardial fibrosis ( P <0.05). Corin overexpression also enhanced heart contractile function (fractional shortening and ejection fraction; P <0.01) and it significantly reduced heart failure as assessed by lung water ( P <0.05) and alveolar congestion ( P <0.001). Consistent with these observations, corin overexpression significantly prolonged life in mice with dilated cardiomyopathy ( P <0.0001). These results provide the first experimental evidence that corin expression plays a role in cardiomyopathy by modulating myocardial fibrosis, cardiac function, heart failure, and survival.

1 September 2009 in Circulation
Verified
Journal Article
Closed access
PDF file
SKSarah M. King
Sarah M. King
RMRachel A. McNamee
Rachel A. McNamee
AHAiilyan K. Houng
Aiilyan K. Houng
RPRakesh Patel
Rakesh Patel
MBMichael Brands
Michael Brands
EGElisabeth Georges-Labouesse
Elisabeth Georges-Labouesse
Background— Platelet aggregation plays a critical role in myocardial infarction and stroke; however, the role of platelet secretion in atherosclerotic vascular disease is poorly understood. Therefore, we examined the hypothesis that platelet dense-granule secretion modulates thrombosis, inflammation, and atherosclerotic vascular remodeling after injury. Methods and Results— Functional deletion of the Hermansky-Pudlak syndrome 3 gene (HPS3 −/− ) markedly reduces platelet dense-granule secretion. HPS3 −/− mice have normal platelet counts, platelet morphology, and α-granule number, as well as maximal secretion of the α-granule marker P-selectin; however, their capacity to form platelet-leukocyte aggregates is significantly reduced ( P <0.05). To examine the role of platelet dense-granule secretion in these processes, atherosclerosis-prone mice with combined genetic deficiency of apolipoprotein E and HPS3 (ApoE −/− , HPS3 −/− ) were compared with congenic, atherosclerosis-prone mice with normal platelet secretion (ApoE −/− , HPS3 +/+ ). After 16 to 18 weeks on a high-fat diet, both groups of mice had similar fasting cholesterol levels and body weight. Carotid arteries of ApoE −/− , HPS3 +/+ mice thrombosed rapidly after FeCl 3 injury, but ApoE −/− , HPS3 −/− mice were completely resistant to thrombotic arterial occlusion ( P <0.01). Three weeks after injury, neointimal hyperplasia (from α-smooth muscle actin–positive cells) was significantly less ( P <0.001) in arteries from ApoE −/− , HPS3 −/− mice. In ApoE −/− , HPS3 −/− mice, there were also pronounced reductions in arterial inflammation, as indicated by a 74% decrease in CD45-positive leukocytes ( P <0.01) and a 73% decrease in Mac-3–positive macrophages ( P <0.05). Conclusions— In atherosclerotic mice, reduced platelet dense-granule secretion is associated with marked protection against the development of arterial thrombosis, inflammation, and neointimal hyperplasia after vascular injury.

1 September 2007 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
GHGordon S. Huggins
Gordon S. Huggins
JLJohn J. Lepore
John J. Lepore
SGSarah Greytak
Sarah Greytak
RPRichard Patten
Richard Patten
RMRachel McNamee
Rachel McNamee
GRGuy L. Reed
Guy L. Reed
Signaling through cAMP plays an important role in heart failure. Phosphorylation of cAMP response element binding protein (CREB) at serine-133 regulates gene expression in the heart. We examined the functional significance of CREB-S133 phosphorylation by comparing transgenic models in which a phosphorylation resistant CREB-S133A mutant containing either an intact or a mutated leucine zipper domain (CREB-S133A-LZ) was expressed in the heart. In vitro, CREB-S133A retained the ability to interact with wild-type CREB, whereas CREB-S133A-LZ did not. In vivo, CREB-S133A and CREB-S133A-LZ were expressed at comparable levels in the heart; however, CREB-S133A markedly suppressed the phosphorylation of endogenous CREB, whereas CREB-S133A-LZ had no effect. The one-year survival of mice from two CREB-S133A-LZ transgenic lines was equivalent to nontransgenic littermate control mice (NTG), whereas transgenic CREB-S133A mice died with heart failure at a median 30 wk of age (P < 0.0001). CREB-S133A mice had an altered gene expression characteristic of the failing heart, whereas CREB-S133A-LZ mice did not. Left ventricular contractile function was substantially reduced in CREB-S133A mice versus NTG mice and only modestly reduced in CREB-S133A-LZ mice (P < 0.02). When considered in light of other studies, these findings indicate that overexpression of the CREB leucine zipper is required for both inhibition of endogenous CREB phosphorylation and cardiomyopathy in this murine model of heart failure.

1 March 2009 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
PDF file
AHAiilyan K. Houng
Aiilyan K. Houng
RMRachel A. McNamee
Rachel A. McNamee
AKAttila Kerner
Attila Kerner
PSPallavi Sharma
Pallavi Sharma
AMAlmois Mohamad
Almois Mohamad
GRGuy L. Reed
Guy L. Reed
Acute coronary artery occlusion triggers the release of atrial natriuretic peptide (ANP) from the heart. ANP affects vasodilation, natriuresis, and inflammation, but the integrated biological effects of ANP on myocardial infarction are unknown. To elucidate these effects, the left anterior coronary artery was ligated in anesthetized, ANP-deficient (ANP−/−) and congenic wild-type (ANP+/+) mice. The survival of ANP−/− mice was markedly better (56%) at 30 days postinfarction than the survival of ANP+/+ mice (20%, P < 0.01). Surviving mice were comparable initially, but ANP−/− mice developed more cardiac hypertrophy ( P < 0.001) and had lower contractility indexes 30 days after infarction ( P < 0.05). An analysis 24 h after coronary occlusion showed that ANP−/− mice had smaller infarcts than ANP+/+ mice (62.6 ± 12.1 vs. 100.8 ± 3.8%, P < 0.001) adjusted for comparable areas at risk for ischemia. The administration of ANP to ANP−/− mice via osmotic minipumps significantly enlarged infarct size to levels comparable with those observed in ANP+/+ mice ( P < 0.05). There was no difference in neutrophil migration into the noninfarcted myocardium of ANP−/− mice undergoing actual versus sham-operated coronary occlusion. By comparison, after coronary occlusion, the neutrophil infiltration into the myocardium was enhanced in ANP+/+ ( P < 0.0005) and ANP−/− mice administered ANP ( P < 0.0005). The expression of P-selectin, a molecule that mediates neutrophil adhesion, was significantly greater after coronary occlusion in the vasculature of ANP+/+ or ANP−/− mice treated with ANP than in ANP−/− mice ( P < 0.002). Taken together, these results indicate that ANP increases P-selectin, neutrophil infiltration, infarct size, and mortality following experimental coronary occlusion.

23 July 2009 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
ISI. Y. Sazonova
I. Y. Sazonova
RMR. A. Mcnamee
R. A. Mcnamee
AHA. K. Houng
A. K. Houng
SKS. M. King
S. M. King
LHL. Hedstrom
L. Hedstrom
GRG. L. Reed
G. L. Reed
Summary. Background: Given the worldwide epidemic of cardiovascular diseases, a more effective means of dissolving thrombi that cause heart attacks, could markedly reduce death, disability and healthcare costs. Plasminogen activators (PAs) such as streptokinase (SK) and tissue plasminogen activator (TPA) are currently used to dissolve fibrin thrombi. SK is cheaper and more widely available, but it appears less effective because it lacks TPA’s fibrin‐targeted properties that focus plasminogen activation on the fibrin surface. Objective: We examined whether re‐programming SK’s mechanism of action would create PAs with greater fibrin‐targeting and potency than TPA. Methods and Results: When fibrinogen consumption was measured in human plasma, reprogrammed molecules SKΔ1 and SKΔ59 were 5‐fold and > 119‐fold more fibrin‐dependent than SK (P < 0.0001), and 2‐fold and > 50‐fold more fibrin‐dependent than TPA (P < 0.001). The marked fibrin‐targeting of SKΔ59 was due to the fact that: (i) it did not generate plasmin in plasma, (ii) it was rapidly inhibited by α2‐antiplasmin, and (iii) it only processed fibrin‐bound plasminogen. To assess the fibrin‐targeting and therapeutic potential of these PAs in vivo, a novel ‘humanized’ fibrinolysis model was created by reconstituting plasminogen‐deficient mice with human plasminogen. When compared with TPA, SKΔ1 and SKΔ59 were 4‐fold (P < 0.0001) and 2‐fold (P < 0.003) more potent at dissolving blood clots in vivo, respectively, on a mass‐dose basis and 2–3 logs more potent than TPA (P < 0.0001) when doses were calibrated by standard activity assays. Conclusion: These experiments suggest that reprogramming SK’s mechanism of action markedly enhances fibrin‐targeting and creates, in comparison with TPA, activators with greater fibrinolytic potency.